ArticleJournal of applied clinical medical physics2026
Feasibility study of three-dimensional dose prediction of esophageal cancer radiotherapy based on CGAN.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the feasibility of a Conditional Generative Adversarial Network (CGAN)-based model (2UDCNN-AT-GAN) for predicting 3D radiotherapy dose distributions in esophageal cancer, and to assess its potential utility as a guidance tool for Intensity-Modulated Radiotherapy (IMRT) plan design.
methodsA CGAN-based model was trained on 95 esophageal cancer IMRT plans and tested on 15 plans. The model integrated a dual-path encoder-decoder, attention-gated fusion, and Dose-volume histogram (DVH)-based conditioning. Predicted dose distributions were compared with manual clinical plans using DVH metrics, plan evaluation parameters, and error analysis.
resultsAll predicted plans met clinical constraints (100% qualification rate). Predicted and manual plans identified concordant near-limit organs at risk (OARs) cases. This consistency mirrored the critical OAR constraints that govern target dose distribution. The mean prediction error was 2.88 ± 2.88% with target errors of 1.00 ± 1.00%. The homogeneity index (0.08 ± 0.02) matched that of manual plans, while the conformity index (CI) was slightly lower (p = 0.0034). The mean Dice Similarity Coefficient (DSC) was 0.916.
conclusionIn this feasibility study, the 2UDCNN-AT-GAN model generated preliminary clinically acceptable dose predictions that met basic clinical constraints and showed spatial similarity to manual plans. A systematic ablation study confirmed that the integrated dual-path and attention-gated architecture outperforms individual components, establishing proof-of-concept feasibility for esophageal IMRT planning guidance. However, systematic target underdosage and the single-institution scope limit its current role to a preliminary planning reference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.